Product Images Nexterone (amiodarone Hci)

Nexterone is an intravenous medication used for treating certain types of irregular heartbeats. It comes in a premixed injection containing 150 mg of amiodarone per 100 mL of isotonic dextrose solution. The solution is in a single-dose container and needs to be discarded after use. The medication contains amiodarone hydrochloride, Batadex Sodium Ether Sulfate, sodium chloride, sodium hydroxide, and dextrose. The solution has to be checked for any leaks before use. The medication should be stored at room temperature and protected from heat and light. It is manufactured by Baxter Healthcare Corporation. *

Nexterone is an intravenous medication containing amiodarone HCI, used to treat certain types of heart rhythm problems. It comes as a premixed injection containing 150 mg of the drug per 100 mL (1.5mg/ml) of an iso-osmotic solution in Dextrose Sterile. Each mL of the solution contains 1.5 mg of amiodarone HCI, USP: 15 mg Betadex Sulfobutyl Ether Sodium, NF. The medication is stored at a temperature between 20°to 25° C (68" to 77° F) and should be protected from too much heat and freezing. Baxter is the manufacturer of the product, which is available in the US only with a prescription. The pack features detailed information on dosage and administration.*

A premixed injection solution called "Nexterone" containing Amiodarone HCI, Betadex Sulfobutyl Ether, citric acid anhydrous, sodium citrate dihydrate and dextrose anhydrous in an iso-osmotic solution of water for injection. It does not contain polysorbate 80 or benzyl alcohol. This solution is used for the treatment of cardiac issues and the instructions for dosage & administration are prescribed in the package insert. It must be stored at 20°C to 25°C to maintain its efficacy. The solution must be protected from freezing and excessive heat. Finally, it is distributed by a company called HF Acquisition Co., LLC based in Mukilteo, Washington, USA.*

Nexterone is an intravenous medication used for the treatment of infections. It comes in a 200mL single-dose container with a code of 263450. Each milliliter of the solution contains 1.8 mg of amiodarone HCI, USP, among other components. The solution must be discarded after use. The medication should not be used beyond the expiration date and must be stored in a temperature-controlled environment, avoiding extreme heat and freezing temperatures. The product must remain in its carton to protect it from light. The solution must not be used with another medication. It may cause harm to the patient if it is not used correctly. Note that a trademark for Nexterone belongs to Baxter International Inc.*

Nexterone is a premixed injection with a strength of 360mg/200mL (1.8mg/mL). It is a sterile, non-pyrogenic and osmotic solution containing amiodarone HCl, Betadax Sulfobuty Eher Sodium, citric acid anhydrous, sodium citrate dihydrate, and dextrose anhydrous with water for injection. It is used as a medication to treat irregular heartbeat or ventricular fibrillation. The medication should be stored at a temperature of 20 to 25°C and the unused portion should be discarded. The product information should be reviewed carefully before use. The package should be protected from light until used. The ANSI certified lot number and expiration date are legible on the package.*

Nexterone is a premixed injection of 360 mg/200 mL of amiodarone hydrochloride that is intended for intravenous use. It has an iso-osmotic solution in Dextrose Sterile, Nonpyrogenic that does not contain polysorbate 80 or benzyl alcohol. The package insert contains complete information on the dosage and administration of the drug. Nexterone is trademarked by Baxter International Inc. The drug should be stored between 20°C to 25°C (68°F to 77°F).*

This is a table displaying adverse reactions in patients who received intravenous amiodarone in controlled and open-label studies, with an incidence greater than 2%. The table presents different studies, including the number of patients in each group, and the total number of individuals involved. It shows adverse reactions, such as fever, bradycardia, congestive heart failure, heart arrest, hypotension, ventricular tachycardia, liver function test abnormality, and nausea, with their respective percentages in each group.*

Formulation not-available.*

This is a table of V-Site Injection Incompatibility featuring a list of drugs with their respective drug-vehicle concentrations such as Amiodarone, Aminopytine, Amonicilin Sodium-Clavulanic Acid, Ampicilin Sodium-Sulbactam Sodium, Argatroban, Bivalirudin, Cefazolin Sodium, Digoxin, Mezlociln Sodium, Imipenem-Cilastin Sodium, Micafungin, Piperacilin Sodium-Tazobactam Sodium, Potassium Phosphates, Sodium Bicarbonate, and Sodium Nizoprusside among others.*

This text provides oral dosage recommendations for patients after an intravenous infusion of NEXTERONE. The initial daily dose depends on the duration of the infusion, with shorter durations requiring higher dosages. The recommended dosages range from 800-1600 mg for infusions lasting less than a week to 400 mg for infusions lasting longer than three weeks. The text also notes that NEXTERONE is not intended for maintenance treatment.*

This text provides recommendations for dosing NEXTERONE as a premixed injection during the first 24 hours of treatment. It outlines loading infusions and maintenance infusion rates, including recommended dosages and rates for direct infusion of the medicament.*

This text provides the concentration of a medication in two different volumes (100 mL and 200 mL) and their respective NDC (National Drug Code) numbers and product code.*